Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
PUMA BIOTECHNOLOGY, INC. FORM 10-K - Biotech Due Diligence
Puma Biotechnology up 15% after quarterly earnings beats (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Exhibitor Puma Biotechnology 02-20 - Scripps CME Connection
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotechnology
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
